Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...

Here are the most important news items that investors need to start their trading day: ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...

Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...